Dibekacin (3',4'-dideoxykanamycin B) is an aminoglycoside antibiotic. It is a semisynthetic derivative of kanamycin developed by Hamao Umezawa and collaborators for Meiji Seika.[1][2]
It has been used in combination with sulbenicillin.[3]
^Umezawa H, Umezawa S, Tsuchiya T, Okazaki Y (July 1971). "3',4'-Dideoxy-Kanamycin B Active Against Kanamycin-Resistant Escherichia coli and Pseudomonas aeruginosa". The Journal of Antibiotics. 24 (7): 485–487. doi:10.7164/antibiotics.24.485. PMID 4998037.
^Umezawa H (November 1982). "Découverte de la dibékacine et de ses aspects chimiques [Discovery of dibekacin and its chemical aspects]". La Nouvelle Presse Médicale. 11 (46): 3379–84. PMID 7155844.
^Aonuma S, Ariji F, Oizumi K, Konno K (June 1987). "Electron microscopy of Pseudomonas aeruginosa treated with sulbenicillin and dibekacin". Tohoku J. Exp. Med. 152 (2): 119–28. doi:10.1620/tjem.152.119. PMID 3114912.
Dibekacin (3',4'-dideoxykanamycin B) is an aminoglycoside antibiotic. It is a semisynthetic derivative of kanamycin developed by Hamao Umezawa and collaborators...
Morales MA, Castrillon JL, Hernandez DA (1993). "Effects of bekanamycin and dibekacin on the electrical activity of cardiac pacemaker cells". Archives of Medical...
Staphylococcus aureus (MRSA). Arbekacin was originally synthesized from dibekacin in 1973 by Hamao Umezawa and collaborators. It has been registered and...
(INN) is a penicillin antibiotic, notable for its combination use with dibekacin. Penicillins, crucial in primary healthcare for potent bactericidal properties...